Drug Type Fc fusion protein, Biosimilar |
Synonyms Aflibercept Biosimilar (GlycoNex, Inc.), Aflibercept-SEA(GlycoNex), 阿柏西普生物类似药(台湾醣联生技医药股份有限公司) |
Target |
Action inhibitors |
Mechanism PGF inhibitors(Placental Growth Factor inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Age Related Macular Degeneration | Preclinical | China | 01 Jan 2023 | |
Eye Diseases | Preclinical | Taiwan Province | 01 Aug 2022 | |
Neoplasms | Preclinical | Taiwan Province | 01 Aug 2022 |